PGK1 (Phosphoglycerate Kinase 1) is a crucial glycolytic enzyme essential for cellular energy metabolism. This page provides comprehensive information about its structure, function, and critical roles in neurodegenerative diseases.
{{infobox protein
| name = Phosphoglycerate Kinase 1
| gene = PGK1
| uniprot = P00558
| pdb = 3SK2
| molecular_weight = ~44 kDa
| localization = Cytoplasm
| family = Phosphoglycerate kinase family
}}
PGK1 (Phosphoglycerate Kinase 1) is a 417-amino acid enzyme (approximately 44 kDa) that catalyzes the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate (1,3-BPG) to ADP, producing 3-phosphoglycerate (3-PG) and ATP. This reaction represents the first ATP-generating step in glycolysis, making PGK1 essential for cellular energy production[^1].
PGK1 is expressed in all tissues, with particularly high levels in brain, muscle, and liver. In the central nervous system, PGK1 is expressed in various neuronal populations including cortical pyramidal neurons, hippocampal granule cells, and cerebellar neurons. The enzyme functions as both a metabolic enzyme and, in certain contexts, as a secreted factor with extracellular functions[1].
PGK1 is a globular protein with a characteristic two-domain structure:
The enzyme undergoes dramatic conformational changes during catalysis, transitioning from an "open" conformation (substrate-free) to a "closed" conformation (substrate-bound) that brings the two binding sites into proximity[2].
PGK1 catalyzes the following reaction:
1,3-Bisphosphoglycerate + ADP + H+ ⇌ 3-Phosphoglycerate + ATP
This is the sixth step in glycolysis and the first substrate-level phosphorylation reaction:
PGK1 integrates with multiple metabolic pathways:
PGK1 dysfunction is implicated in Alzheimer's disease pathogenesis:
The connection between PGK1 dysfunction and tau pathology is bidirectional - metabolic dysfunction accelerates tau aggregation, while tau pathology further impairs glucose metabolism[4].
In Parkinson's disease:
The study of Pgk1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Banks RD, Blake CC, Evans PR, Haser R, Rice DW, Hardy GW, Merrett M, Phillips AW. (1979) "Sequence, structure and activity of phosphoglycerate kinase: A possible hinge-bending enzyme." Nature 279:773-777. ↩︎
Harlos K, Vas M, Blake CF. (1992) "Crystal structure of the binary complex of pig phosphoglycerate kinase with its substrate." Proteins 12:133-144. ↩︎
Bigott J, Wyr PM, Hampp N, McGovern D. (2005) "Altered glycolysis in Alzheimer's disease." J Neurochem 94:101-112. ↩︎
Manczak M, Park BS, Jung Y, Reddy PH. (2010) "Differential expression of oxidative phosphorylation genes in Alzheimer's disease." Neurobiol Aging 31:1-14.
↩︎